Endotoxemia in organ donors: graft function following liver transplantation

2000 ◽  
Vol 13 (0) ◽  
pp. S286-S287 ◽  
Author(s):  
A. Zipfel ◽  
M. Schenk ◽  
M.-S. You ◽  
W. Lauchart ◽  
C. Bode ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Graft Function ◽  
Organ Donors

scholarly journals Endotoxemia in organ donors: graft function following liver transplantation

2000 ◽  
Vol 13 (S1) ◽  
pp. S286-S287 ◽  
Author(s):  
A. Zipfel ◽  
M. Schenk ◽  
M.-S. You ◽  
W. Lauchart ◽  
C. Bode ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Graft Function ◽  
Organ Donors

scholarly journals Discontinuation of Passive Immunization Is Safe after Liver Transplantation for Combined HBV/HDV Infection

Viruses ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 904
Author(s):  
Ramin Raul Ossami Saidy ◽  
Irina Sud ◽  
Franziska Eurich ◽  
Mustafa Aydin ◽  
Maximilian Paul Postel ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Overall Survival ◽  
Hepatitis B ◽  
Graft Function ◽  
Passive Immunization ◽  
Standard Regimen ◽  
Long Term Follow Up ◽  
Hdv Infection ◽  
End Stage

Patients after LT due to combined HBV/HDV infection are considered to be high-risk patients for recurrence of hepatitis B and D. To date, life-long prophylaxis with hepatitis B immunoglobulin (HBIG) and replication control with nucleos(t)ide analogs (NA) remains standard. We examined the course of 36 patients that underwent liver transplantation from 1989 to 2020 for combined HBV/HDV-associated end-stage liver disease in this retrospective study. Seventeen patients eventually discontinued HBIG therapy for various reasons. Their graft function, histopathological findings from routine liver biopsies and overall survival were compared with those that received an unaltered NA-based standard regimen combined with HBIG. The median follow-up was 204 and 227 months, respectively. The recurrence of HBV was 25% and did not differ between the groups of standard reinfection prophylaxis NA/HBIG (21.1%) and HBIG discontinuation (29.4%); (p = 0.56). No significant differences were found regarding the clinical course or histopathological aspects of liver tissue damage (inflammation, fibrosis, steatosis) between these two groups. Overall, and adjusted survival did not differ between the groups. Discontinuation of HBIG in stable patients after LT for combined HBV/HDV did not lead to impaired overall survival or higher recurrence rate of HBV/HDV infection in this long-term follow-up. Therefore, the recommendation of the duration of HBG administration must be questioned. The earliest time of discontinuation remains unclear.

scholarly journals Complement Activation in Liver Transplantation: Role of Donor Macrosteatosis and Implications in Delayed Graft Function

2018 ◽  
Vol 19 (6) ◽  
pp. 1750 ◽  
Author(s):  
Kelley Núñez ◽  
Paul Thevenot ◽  
Abeer Alfadhli ◽  
Ari Cohen
Keyword(s):  
Liver Transplantation ◽  
Complement Activation ◽  
Graft Function ◽  
Delayed Graft Function

scholarly journals Donor des-gamma-carboxy prothrombin positivity is a risk factor for poor early graft function in liver transplantation

1998 ◽  
Vol 11 (2) ◽  
pp. 143-146 ◽  
Author(s):  
Taketoshi Suehiro ◽  
Peter Boros ◽  
Sukru Emre ◽  
Patricia A. Sheiner ◽  
Stephen Guy ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Risk Factor ◽  
Graft Function ◽  
Early Graft

Indocyanine green clearance as a marker of graft function in liver transplantation

1999 ◽  
Vol 31 (6) ◽  
pp. 2447-2448 ◽  
Author(s):  
J. Igea ◽  
J. Nuño ◽  
P. López-Hervás ◽  
Y. Quijano ◽  
A. Honrubia ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Indocyanine Green ◽  
Graft Function ◽  
Indocyanine Green Clearance

Graft Function Measured by Transient Elastography in Living Donor Liver Transplantation: Preliminary

2013 ◽  
Vol 45 (8) ◽  
pp. 3028-3031 ◽  
Author(s):  
S.H. Lee ◽  
D.J. Joo ◽  
S.U. Kim ◽  
M.S. Kim ◽  
A.-L. Lee ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Transient Elastography ◽  
Graft Function ◽  
Donor Liver ◽  
Donor Liver Transplantation

Correlation between effluent hyaluronic acid levels and early graft function in orthotopic liver transplantation

1998 ◽  
Vol 30 (6) ◽  
pp. 2889-2890 ◽  
Author(s):  
J.C Lendoire ◽  
F Duek ◽  
G Bianco ◽  
H Aziz ◽  
J Saúl ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hyaluronic Acid ◽  
Orthotopic Liver Transplantation ◽  
Graft Function ◽  
Early Graft

scholarly journals Effects of cyclosporine A pretreatment of deceased organ donors on kidney graft function (Cis-A-rein): study protocol for a randomized controlled trial

Trials ◽  
2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Jean-Christophe Orban ◽  
◽  
Eric Fontaine ◽  
Elisabeth Cassuto ◽  
Karine Baumstarck ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Study Protocol ◽  
Cyclosporine A ◽  
Controlled Trial ◽  
Graft Function ◽  
Organ Donors ◽  
Kidney Graft ◽  
Randomized Controlled

Liver transplantation

2020 ◽  
pp. 3100-3107
Author(s):  
John G. O’Grady
Keyword(s):  
Liver Transplantation ◽  
Liver Disease ◽  
Antiviral Agents ◽  
Graft Loss ◽  
Graft Function ◽  
Myeloproliferative Disease ◽  
Direct Acting Antiviral ◽  
Tumour Bulk ◽  
Technical Complication ◽  
End Stage

Liver transplantation is an established treatment for liver conditions that broadly fall into the categories of acute liver failure, end-stage chronic liver disease, primary hepatic malignancy, and metabolic disease. The expected 1-year survival rate is over 90% and some patients are alive more than 40 years after transplantation. Disease severity scores for cirrhosis heavily influence selection of patients with cirrhosis for transplantation. The prototype is the MELD (Model for End-Stage Liver Disease) score, based on serum bilirubin, serum creatinine, and INR: a score of 16 is considered the threshold that confers benefit from liver transplantation. Hepatocellular carcinoma accounts for most of the malignancy group and selection is largely determined by tumour bulk assessed by the number and size of lesions. Immunosuppression strategies based on tacrolimus, with or without other drugs including mTOR (mechanistic target of rapamycin) inhibitors, antiproliferative agents, or prednisolone, are highly effective in preventing loss of the graft through classical rejection processes. Recurrence of original disease is the main cause of loss of graft function, with recurrence of hepatitis C a particularly challenging problem, although new direct-acting antiviral agents are likely to radically improve outcomes. Technical problems can also result in graft loss due to hepatic artery thrombosis or diffuse ischaemic cholangiopathy, especially in livers harvested from donors after cardiac death. Anastomotic biliary strictures are the commonest technical complication, with 15 to 20% of patients requiring some form of endoscopic or surgical intervention. There is a considerably increased risk of myeloproliferative disease and skin cancers in transplant recipients, as well as aetiology-specific risk. Many patients die having achieved a normal life expectancy, and death with a functioning graft is the commonest terminal scenario.

Sign in / Sign up

Export Citation Format

Share Document